Background: High-oncogenic-risk human papillomavirus (hrHPV) is
D espite a global reduction in incidence, cervical cancer remains the leading cause of cancer-related mortality in women in Sub-Saharan Africa. 1 Kenya ranks 16th in the world in cervical cancer incidence, with more than 40 annual cases per 100,000 women. 1 Cervical cancer develops as a result of persistent infection with oncogenic high-risk human papillomavirus (hrHPV). In contrast to the observation that hrHPV infection is found in nearly 100% of cervical cancer cases, the likelihood of developing cancer is quite low among women exposed to hrHPV infection. Therefore, hrHPV infection is an essential etiologic cause of cervical cancer, yet hrHPV infection alone is not considered sufficient to cause cancer. These observations suggest that other factors interact with hrHPV to promote cervical cancer development.
Similar to HPV, infection with the human herpesvirus EpsteinBarr virus (EBV) is extremely common and typically asymptomatic, but occasionally leads to epithelial neoplasms, for example, nasopharyngeal carcinoma 2 and gastric carcinoma. 3 Epstein-Barr virus establishes a lifelong infection in its human host, resides in a quiescent (latent) state with periodic lytic reactivation, and has a predilection for mucosal surfaces. [4] [5] [6] Sixbey et al 6 revealed that the female genital tract is a site of EBV shedding by demonstrating the recovery of live, infectious EBV from cervical secretions. Little is known about the biology and natural history of genital EBV infection, or the risk factors for EBV detection from the female genital tract.
The presence of EBV in the female genital tract provides an opportunity for interactions between coexisting hrHPV and EBV infections. Given the ability of EBV to promote epithelial tumor formation, there is a possibility that EBV might act in conjunction with hrHPV infection to facilitate the oncogenic potential of hrHPV and, as such, the progression of low-grade cervical dysplasia to high-grade cervical dysplasia or cancer. In this study, we used stored samples from a high-risk cohort of Kenyan women who had previously undergone cervical HPV testing to examine the association between detection of EBVand hrHPVat baseline, and the diagnosis of abnormal cervical cytology at baseline and over study follow-up.
MATERIALS AND METHODS

Study Population
This study used archived specimens collected as part of a research study investigating approaches to cervical cancer screening in a high-risk cohort of African women. Participants in the study were female sex workers (FSWs) attending the Korogocho health clinic in Nairobi, Kenya, from 2009 to 2011, as previously described. 7 Baseline specimens (n = 332) were used for this study. Sociodemographic and behavioral characteristics were collected at baseline. Specimen results from participants followed up prospectively at 6-month intervals for 2-year study follow-up, and results of HPV testing and cytology were included in time-to-event analyses.
Enrollees provided informed consent. The primary study protocol was approved by local institutional review boards (IRBs) and the IRB of the University of North Carolina and was conducted in accordance with all applicable ethical standards for research on human subjects. Further approval for the analysis presented herein was obtained from the IRB of the LSU Health Sciences Center, New Orleans.
Specimens, Clinical Evaluation, and Laboratory Testing
Specimens collected included a physician-collected cervical brush and a conventional Papanicolaou test, as previously described. 7 Cytologic smears were evaluated by 2 independent cytopathologists and were classified according to the 2001 Bethesda System. Lowgrade cervical abnormalities were defined as atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions (LSILs), and high-grade abnormalities included high-grade squamous intraepithelial lesions (HSILs) and cancer. Cervical abnormalities overall were defined as ≥ASCUS. Cervical brush specimens were tested for hrHPV using the APTIMA HPV test (Hologic Inc, San Diego, CA), which indiscriminately detects the presence of E6/E7 mRNA transcripts of hrHPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , 66, and 68. Women were also tested for sexually transmitted infections (STIs) including Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) by APTIMA Combo-2 assay, Trichomonas vaginalis (TV) by APTIMA TV assay, and Mycoplasma genitalium (MG) by APTIMA MG assay (research use only). Testing for HIV serum antibodies was performed by enzyme-linked immunosorbent assay.
To prepare the samples for EBV molecular testing, genomic DNA (including viral and host DNA) was isolated from a 1.5-mL aliquot of cervical brush specimen in PreservCyt transport media (Cytyc Corp, Marlborough, MA) using the QIAamp DNA Minikit (Qiagen NV, Hilden, Germany) according to the manufacturer's protocol. Samples that tested positive for β-globin DNA via polymerase chain reaction (PCR) amplification (n = 330; 99.4%) were tested for EBV by PCR amplification of the BamH1-W repeats, a multicopy region of the EBV genome. 8 Presence of a 192-bp product on 2% agarose gel indicated the presence of EBV. Results were interpreted by 2 independent and blinded observers.
Statistical Analysis
The prevalence of HIV, hrHPV mRNA, and EBV DNA were estimated for the 330 women with baseline EBV test results. Because HIV infection is likely to promote HPV persistence and might influence frequency and duration of EBV detection, we conducted analyses that adjusted for or stratified by HIV status. Cervical cytology was performed on all women at baseline and during follow-up, and therefore, we chose cervical cytology as the primary clinical outcome for our analysis. In this cohort, cervical biopsy/histopathology was only performed on women with a cytology diagnosis of HSIL or LSIL/ASCUS/AGUS diagnosis at 2 consecutive visits. The prevalence of high-grade cervical cytology at baseline stratified by hrHPVand EBV coinfection status was estimated, overall and by HIV status. Prevalence ratios (PRs [95% confidence interval {CI}]) were calculated using log-binomial regression to determine risk factors associated with EBV detection. Log-binomial regression was also used to estimate the association between EBV and hrHPV, cervical abnormalities, and high-grade lesions overall and adjusted for HIV status.
For longitudinal analyses, the observation period comprised 5 clinic visits at 6-month intervals over 24 months. Crude and adjusted risk ratios (RRs) compared the incidence of cervical abnormalities and worsening of cervical cytology (defined as progression from normal to abnormal cytology or from low-grade or ASCUS to high-grade cytology) by EBV status. Women with prevalent high-grade abnormalities at baseline were referred for treatment and were excluded from the study. Women with incident high-grade abnormalities during observation were also referred for immediate treatment but were included in the analysis as a study end point of progression.
We conducted time-to-event analysis in which risk of hrHPV persistence was indicated by a ratio of the time to hrHPV clearance, comparing women with baseline EBV infections with women without baseline EBV infections. A time ratio (TR) greater than the null value (i.e., TR > 1.0) indicates that the time to clearance of an hrHPV infection was longer in the EBV-infected group compared with the EBV-uninfected group. Crude and adjusted TRs estimated the (1) relative time to clearance of hrHPV infection and (2) relative time to regression of cervical lesions (defined as change from any abnormal cytology to normal cytology at a subsequent visit) comparing EBV-positive with EBV-negative participants.
The risk period for clearance began when hrHPV was first detected. The calculation was based on the number of intervals from the first positive hrHPV test result until at least one subsequent hrHPV test result was negative, or until the participant was lost to follow-up. Relative time to clearance of hrHPV was estimated using a minimum time to clearance (beginning at enrollment and ending just after the last positive hrHPV result) and a maximum time to clearance (the minimum time plus the additional unobserved time between the dates of the last positive hrHPV result and the first negative hrHPV result). Time to regression of cervical lesions was computed using the same strategy. Further details of the statistical considerations have been previously published. 9 Missing cytologic results were imputed when the results in the visits before and after the missing visit were identical. For time to clearance of hrHPV, missing data were handled by right-censoring observations that had missed 2 or more consecutives study visits after a positive hrHPV diagnosis (lost to follow-up) and by imputing data for single missing visits, carrying over the last observed value for hrHPV status. We conducted sensitivity analyses excluding severely immunosuppressed participants (CD4 + T-cell counts <200; n = 6). Adjustment variables for all analyses were determined based on a review of the literature and analysis of causal diagrams. All analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, NC).
RESULTS
Participant Characteristics
The median age of the 330 participants in this study was 28.5 years (range, 25-34 years; Table 1 ). In this high-risk cohort of women, the majority had only a primary education or less (76%), 
Relationship Between hrHPV, EBV, and Cervical Cytology
We examined the relationships between viral infections (hrHPV, EBV, and HIV) and cervical cytology. High-risk HPV E6/E7 mRNA and EBV DNA were concurrently detected in the cervical specimens of 32 women (9.7%; Table 2 ). Of the coinfected women, 65.6% were also infected with HIV. Women were over twice as likely to test positive for cervical hrHPV if they were also EBV DNA positive (PR, 2.1 [1.5-2.9]). This association was attenuated when adjusting for HIV infection status (adjusted PR, 1.8 [1.3-2.6]) but remained significant.
Epstein-Barr virus-positive women had a higher prevalence than did EBV-negative women of high-grade precancer (15% vs. 2%) and abnormal cytology (37% vs. 15%; Fig. 1 ). However, when adjusted for hrHPVand HIV status, EBV was not independently associated with high-grade cervical cytology (adjusted PR, 2.0 [0.7-5.9] or abnormal cytology (adjusted PR, 1.4 [0.9-2.2]; Table 2). Further adjusting for smoking and age did not appreciably change the magnitude of these estimates or alter the conclusions. However, among women who were hrHPV positive, those who tested positive for EBV DNA were significantly more likely to have abnormal cervical cytology compared with women with hrHPV alone (53% vs. 20%, P = 0.01; Fig. 1 ). This observation was more pronounced in women who were HIV positive than in women who were HIV negative (Figs. 1B, C, respectively). One quarter of women (25%) with cervical hrHPV-EBV coinfection had concurrent high-grade cytology. By comparison, 7.6% of women with hrHPV alone had concurrent high-grade cytology (Fisher exact test, P = 0.027).
Relationship Between Cervical EBV Positivity at Baseline and Natural History of hrHPV Infection or Cervical Abnormalities
A marginal and nonsignificant association was observed between baseline EBV positivity and risk of acquiring hrHPV infection during the 24-month observation period, when adjusting for HIV status and age (data not shown). Similarly, baseline EBV positivity was not a significant positive predictor of incident cervical abnormalities, even in women testing positive for hrHPV at baseline (Table S1 , http://links.lww.com/OLQ/A267). Baseline EBV positivity was associated with worsening cervical health status during observation (age and HIV status adjusted RR, 2.21 [1.00-4.90]), but the association was not significant when further adjusting for hrHPV status, or when restricting the analysis to women who were hrHPV positive at baseline (Table S1 , http://links.lww.com/OLQ/A267).
In a sensitivity analysis excluding women with CD4 + T-cell counts less than 200 cells/mL (n = 6), associations between baseline EBV positivity and (1) The median follow-up time was 26.2 months (IQR, 18.8-27.5 months), and the median time to clearance of hrHPV infection was 9.4 months (IQR, 5.9-19.5 months). Women with baseline EBV infections had a median time to hrHPV clearance of 22.6 months, and women without baseline EBV infections had a median time to hrHPV clearance of 9.4 months. After adjusting for baseline HIV status and age, baseline EBV positivity was marginally associated with longer time to clearance of hrHPV infection among women who were coinfected with hrHPV at baseline (adjusted TR, 1.60 [1.00-2.55]; Table 3 ). In a sensitivity analysis excluding women with low CD4 + T-cell counts (<200 cells/mL), we observed a slight attenuation of the association between EBV positivity and time to clearance of hrHPV infection (adjusted TR Table 3 ).
DISCUSSION
In this cohort of FSWs in Nairobi, Kenya, we found that women testing positive for both hrHPV and EBV had a significantly higher prevalence of concurrent cervical abnormalities (overall and for high-grade precancer) compared with women infected with hrHPV alone. This difference was most pronounced in HIV-infected women. In addition, cervical EBV detection was seen more often in HIV-positive women and those with hrHPV infection. Finally, in prospective analyses, the presence of EBV was marginally associated with delayed resolution of hrHPV infection and progression to more severe cytology. Prevalence of EBV detection at the cervix in this cohort of Kenyan FSWs was 19% among all women, with notably high detection among HIV-positive women at baseline (44%). In comparison, EBV prevalence ranged widely (9%-42%) in cervical samples of healthy women, [10] [11] [12] [13] whereas cervical EBV prevalence in women attending sexually transmitted disease clinics exceeded 25%. 8, 14 The prevalence of cervical EBV infection was reportedly 10% in an Italian cohort of women with HIV infection. 15 Finally, in a large cohort of women seeking gynecologic care in rural India, the prevalence of cervical EBV detection was 20%. 16 The highly variable prevalence rates of cervical EBV detection are likely attributable to differences in age, geographical location, sociodemographic risk factors, and laboratory testing methods among published studies.
There are limited published data describing factors associated with genital tract EBV detection. In the present study and in a study from India, older age was significantly associated with a higher rate of detection of EBVat the cervix. 16 In our study, women who tested positive for STIs, including HIV, were more likely to be EBV positive at the cervix. In particular, infection with MG was associated with a higher detection of EBV, as was recently reported among HIV-infected women from New Orleans. 17 Failure to consistently use condoms was also significantly associated with higher EBV prevalence in our study, possibly due to increased exposure to STIs. The association of EBV with sexually transmitted pathogens could indicate that EBV is being deposited at the cervix during sexual intercourse, similar to the sexual transmission route of the more traditional STI pathogens. Alternatively, because the reservoir of latent EBV is memory B cells, 18 Epstein-Barr virus could be a passenger in infiltrating lymphocytes trafficking to the cervix in response to infection and/or associated cervical pathology. Our study was not designed to distinguish between these 2 possibilities.
In our cohort, we found that women positive for hrHPV were twice as likely to have an abnormal cytology result or highgrade precancer if they were simultaneously positive for EBV at the cervix. This relationship was even stronger in women with HIV. Despite differences in geographic location, population, sampling, and testing methods, our data corroborate the findings of other investigators. In the rural Indian population, cervical EBV detection was associated with a positive test result for HPV and abnormal cytology, as in our study, whereas detection of the cytomegalovirus was not associated with cervical screening test outcomes. 16 The authors found that a biopsy-confirmed histologic diagnosis of cervical intraepithelial neoplasia was a significant positive predictor of cervical EBV detection after adjusting for other factors, including age, with an adjusted PR of 3.92 (95% confidence interval, 2.49-6.16). Among HIV-seropositive Italian women with HPV infection, prevalence of abnormal cytology was higher in women testing positive for EBV and HPV (76% vs. 67% in women with HPValone). This finding was not statistically significant, possibly owing to immune suppression (average CD4 + T-cell count, 291 cells/mL) leading to unusually high rates of abnormal cytology in the HIV-HPV-coinfected women. 15 Results of our sensitivity analyses excluding women with CD4 + T-cell counts less than 200 found similar associations between EBV positivity and risk of prevalent cervical abnormalities, although the excess time to hrHPV clearance observed among participants testing positive for EBV may have partially been driven by a small number of participants with severe HIV-associated immune suppression, as HIV-infected participants in our sample were generally not severely immunocompromised (median CD4 + T-cell count [IQR] , 507 ). Limitations of this study included insufficient follow-up time for some women to experience definitive outcomes and a low incidence of high-grade cytology. In addition, the impact of false-negative test results for EBV or HPV would be that some women with abnormal cytology may have falsely tested negative for 1 of the 2 viruses. This would lead to misclassification and subsequent underestimation of the risk of abnormal cytology associated with viral coinfection. False-negative classification of a single cytology result (i.e., normal cytology when in fact an abnormality exists) is another potential source of misclassification bias. Using the criterion standard histopathology diagnosis of cervical biopsy tissue would improve diagnostic certainty and might also alter the results of our analysis. We conducted a sensitivity analysis for Table 2 in which we reclassified baseline high-grade cervical abnormalities based on histopathology results (i.e., comparing CIN2+ vs. CIN1, normal histology or normal cytology). We identified 4 additional CIN2+ outcomes, which gave more power to detect a difference in prevalence of high-grade cervical abnormalities by EBV status (HIV-and hrHPV-adjusted PR, 2.63 [1.01-6.84]). However, because not all participants had histopathology data, we opted for cytology as our primary clinical outcome for consistency and to avoid verification bias.
Previous reports of cervical EBV detection and cervical abnormalities in the context of HPV infection have assessed HPV status by detection of viral DNA using highly sensitive PCR assays. 8, 15, [19] [20] [21] [22] [23] [24] Sensitive DNA-based assays would detect both productive, clinically relevant infection and unproductive, clinically benign hrHPV (i.e., recent deposition in the absence of true infection). Our study defined hrHPV infection by detection of E6/E7 mRNA transcripts, which is more indicative of a productive and clinically relevant hrHPV infection. If EBV promotes cervical abnormalities by inducing expression of hrHPV E6/E7 transcripts, then restricting the analysis to infections with detectable E6/E7 transcripts could underestimate the potential role of EBV in promoting productive hrHPV infections and corresponding abnormalities.
To our knowledge, this is the first prospective study that attempts to determine associations between EBV detection at the cervix and hrHPV persistence and cervical dysplasia outcomes. Despite the aforementioned limitations to our study, we observed trends that would suggest that EBV at the cervix may alter the natural history of hrHPV infection and cervical abnormalities. Alternatively, EBV detection at the cervix may be a correlate of other biological processes that portend the outcome of cervical dysplasia in the absence of a direct causal role in promoting disease. Larger prospective cohort studies with longer observation periods will be necessary to clarify the associations between cervical EBV detection and hrHPV persistence or progression of cervical abnormalities. Further studies are also warranted to determine whether or not EBV plays a direct role in the pathogenesis of hrHPVmediated cervical abnormalities and cancer. Time to clearance is calculated from the first visit at which a positive hrHPV test result was obtained until the next visit at which a negative hrHPV test result was obtained. ‡ Time to resolution is calculated from baseline until the first visit at which a normal cervical cytology result was obtained.
